Tiziana Life Sciences Ltd (NASDAQ:TLSA) has withdrawn its proposed public offering of common shares, citing market conditions.
The company, focused on immunomodulation therapies with its lead intranasal foralumab, a fully human anti-CD3 monoclonal antibody, confirmed that this announcement does not constitute an offer or solicitation to buy or sell securities in any jurisdiction where such actions would be unlawful.